Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

1. WO2012009705 - COMPLEXES LIANT ANG-2 ET LEURS UTILISATIONS

Numéro de publication WO/2012/009705
Date de publication 19.01.2012
N° de la demande internationale PCT/US2011/044290
Date du dépôt international 15.07.2011
Demande présentée en vertu du Chapitre 2 15.05.2012
CIB
C07K 16/22 2006.01
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
16Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
18contre du matériel provenant d'animaux ou d'humains
22contre des facteurs de croissance
C07K 16/24 2006.01
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
16Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
18contre du matériel provenant d'animaux ou d'humains
24contre des cytokines, des lymphokines ou des interférons
C07K 16/28 2006.01
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
16Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
18contre du matériel provenant d'animaux ou d'humains
28contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 38/10 2006.01
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
38Préparations médicinales contenant des peptides
04Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminée; Leurs dérivés
10Peptides ayant de 12 à 20 amino-acides
C07K 7/08 2006.01
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
7Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminée; Leurs dérivés
04Peptides linéaires ne contenant que des liaisons peptidiques normales
08ayant de 12 à 20 amino-acides
C07K 19/00 2006.01
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
19Peptides hybrides
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 47/6811
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
6811the drug being a protein or peptide, e.g. transferrin or bleomycin
A61K 47/6813
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
6811the drug being a protein or peptide, e.g. transferrin or bleomycin
6813the drug being a peptidic cytokine, e.g. an interleukin or interferon
A61K 47/6843
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6843the antibody targeting a material from animals or humans
A61K 47/6845
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6845the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
A61K 47/6849
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6849the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
Déposants
  • ZYNGENIA, INC. [US/US]; 21 First Field Road, Suite 200 Gaithersburg, MD 20878, US (AllExceptUS)
  • ROSCHKE, Viktor [US/US]; US (UsOnly)
  • LAFLEUR, David [US/US]; US (UsOnly)
  • HILBERT, David, M. [US/US]; US (UsOnly)
  • KIENER, Peter [US/US]; US (UsOnly)
Inventeurs
  • ROSCHKE, Viktor; US
  • LAFLEUR, David; US
  • HILBERT, David, M.; US
  • KIENER, Peter; US
Mandataires
  • SHEA, JR., Timothy, J.; Sterne, Kessler, Goldstein & Fox P.L.L.C. 1100 New York Avenue, N.W. Washington, DC 20005-3934, US
Données relatives à la priorité
61/364,76415.07.2010US
61/364,76515.07.2010US
61/364,76615.07.2010US
61/364,77115.07.2010US
61/364,77415.07.2010US
61/383,64416.09.2010US
61/481,06329.04.2011US
61/485,48412.05.2011US
61/485,48612.05.2011US
61/485,50212.05.2011US
61/485,50512.05.2011US
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) ANG-2 BINDING COMPLEXES AND USES THEREOF
(FR) COMPLEXES LIANT ANG-2 ET LEURS UTILISATIONS
Abrégé
(EN)
Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffolds including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described.
(FR)
L'invention concerne des complexes contenant un ou plusieurs domaines de reconnaissance modulaires (DRM) et des DRM attachés sur des échafaudages comprenant des anticorps. L'invention concerne également la fabrication de ces complexes et l'utilisation de ces complexes pour traiter et diagnostiquer des maladies et des troubles.
Dernières données bibliographiques dont dispose le Bureau international